Europe Biodefense Market Outlook, 2030

The European biodefense market is experiencing substantial growth, driven by the increasing recognition of biological threats, both natural and man-made, and the imperative to bolster regional biosecurity. This market encompasses a wide range of products and services, including vaccines, biothreat detection devices, antibiotics, and personal protective equipment, all aimed at safeguarding public health and national security. The rise in naturally occurring outbreaks, coupled with the persistent threat of bioterrorism, has prompted European governments to invest heavily in biodefense infrastructure and research. The region's advanced healthcare systems and robust pharmaceutical industry provide a strong foundation for the development and deployment of innovative biodefense solutions. Furthermore, the increasing integration of advanced technologies, such as genomics, proteomics, and artificial intelligence, is enhancing the capabilities of biothreat detection and response systems. The European Union's focus on public health security and cross-border collaboration is also driving market growth, with initiatives aimed at strengthening disease surveillance, stockpiling critical medical supplies, and coordinating emergency response efforts. The COVID-19 pandemic has underscored the vulnerability of European societies to biological threats, accelerating the demand for robust biodefense measures and prompting significant investments in vaccine development and production. The market is also influenced by geopolitical factors, including the increasing threat of biological weapons proliferation and the need to protect critical infrastructure from biological attacks. The ongoing advancements in biotechnology and genetic engineering, while offering immense potential for medical breakthroughs, also necessitate enhanced biodefense capabilities to mitigate the risks associated with the potential misuse of these technologies. European governments are actively engaging in policy initiatives and strategic planning to address these challenges, fostering collaboration between public and private sector stakeholders to develop and deploy effective biodefense solutions. The market's growth is further supported by the increasing awareness of the interconnectedness of human, animal, and environmental health, leading to a One Health approach that integrates multiple disciplines to address biological threats. The European biodefense market is poised for continued expansion, driven by the imperative to safeguard public health and national security in an increasingly complex and interconnected world.

According to the research report " Europe Biodefense Market Overview, 2030," published by Bonafide Research, the Europe Biodefense Market is anticipated to grow at more than XXXX% CAGR from 2025 to 2030. Biodefense is referred to the measures taken to restore biosecurity of a group of organisms that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care. Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030 owing to the rising need for biodefense agents and equipment in the region. The rise in naturally occurring outbreaks, the threat posed by biological weapons, and the development of ICBMs with nuclear warheads are the main reasons why the biodefense market is expanding. Restrictive constraints, such as financial swings brought on by a changing EU, are anticipated to hinder market expansion in the years to come. The growth of biopharmaceuticals contract manufacturing is also anticipated to increase throughout the forecast period due to the rising implementation of technology and predictive analytics to redefine the biodefense market. The government spends a lot of money each year on vaccine research and development in order to be ready for potential bioterrorism threats. The UK government, for instance, published several documents in 2018: the Biological Security Strategy, Strategic Defense and Security Review, Global Health Security, UK Antimicrobial Resistance Strategy, National Counterterrorism Strategy, Counterterrorism Strategy CONTEST, National Counter-Proliferation Strategy to 2020, UK Influenza Preparedness Strategy, Strategy for UK Life Sciences, Vision, and High Level Strategy for UK Animal and Plant Health Research to 20.
Covid-19 Impact
The global struggle to tackle the COVID-19 pandemic has exposed the vulnerability of global societies to natural and manmade biological threats, prompting experts to warn of a potential increase in the use of biological weapons, like viruses or bacteria, in a post-coronavirus world. As a result of this the European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. All of these factors along with the plan to be prepared for the future has driven investors with large sum of money to the European Biodefence market, providing its further growth in the future
Highlighted with 35 tables and 41 figures, this 109-page report “Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
By Product type
• Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines
• Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
• Antibiotics
• Masks
• Other Products
By Sales Channel
• Online Sales
• Offline Sales
By Application
• Military
• Civilian
By Geography
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation,

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sunny Keshri

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now